Motivated by this encouraging data, the lung SORT LNPs were further assessed for their therapeutic potential for treatment of cystic fibrosis (CF), a genetic lung disease caused by a C-to-T mutation in the cystic fibrosis transmembrane conductance regulator (CFTR). The gene discussed is CFTR; the disease is cystic fibrosis.